On the heels of raising $44 million in a Series C Round, MediciNova Inc. filed with the SEC to raise $100 million in an initial public offering in Japan, where it was founded four years ago as a subsidiary of Tanabe Seiyaku Co. Ltd., of Osaka. (BioWorld Today)

A bit of you know what at the end of the tunnel came for Miravant Medical Technologies Inc. in the form of an approvable letter for its light-activated drug to treat age-related macular degeneration, although the FDA is asking for another confirmatory trial. (BioWorld Today)

Tarceva, the eye-opening cancer drug with a new drug application pending, typically is regarded as another feather in the cap of Genentech Inc., whose headgear already is festooned with plumage.